Ocular implant containing a tyrosine kinase inhibitor
AssigneeOcular Therapeutix, Inc.
InventorsCharles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Life of this patent
Estimating the term…
Abstract
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Claims27
A sustained release biodegradable ocular implant comprising a hydrogel and a dose of axitinib from about 150 μg to about 1200 μg, wherein the axitinib is dispersed within the hydrogel, and wherein the implant in its dry state prior to implantation is cylindrical;
- has a length of about 6 mm to about 17 mm and a diameter of 0.2 mm to 0.5 mm;
- and has a total implant weight of about 0.2 mg to about 1.5 mg.
A sustained release biodegradable ocular implant comprising a hydrogel and a dose of axitinib from about 150 μg to about 1200 μg, wherein the axitinib is dispersed within the hydrogel, and wherein the implant in its dry state prior to implantation is cylindrical;
- has a length of about 6 mm to about 17 mm and a diameter of 0.2 mm to 0.5 mm;
- has a total weight of about 0.2 mg to about 1.5 mg;
- provides for the release of axitinib at an average rate of about 0.1 μg to about 3 μg per day in phosphate-buffered saline at a pH of 7.2 and 37° C. under non-sink simulated physiological conditions;
- and in its dry state contains from about 200 μg to about 900 μg axitinib per mm3.
Dependencies are inferred from the claim text.